Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 12/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 12/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.49 |
| ▸ | PDE2A | O00408 | 8/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11520 | 0.87 | BACE1 (0.70) | BACE1PDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL14297341 | 0.70 | NPC1 (0.55) | S1PR1MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL9829 | 0.69 | BACE1 (1.00) | BACE1 | |
| Methane SCHEMBL10505710 | 0.64 | BACE1 (0.61) | BACE1PDE3BPDE3AP2RY12MEN1 | |
| SCHEMBL10723835 | 0.63 | ALDH1A1 (0.59) | BACE1PDE3BPDE3AMEN1NPC1 | |
| SCHEMBL6700312 | 0.63 | ME2 (0.35) | — | |
| SCHEMBL6700320 | 0.63 | ME2 (0.35) | — | |
| SCHEMBL2407533 | 0.63 | KCNH2 (0.49) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL14950289 | 0.63 | FAAH (0.66) | S1PR1NPC1RAB9ATP53POLB | |
| SCHEMBL13956186 | 0.62 | MEN1 (0.49) | MAP4K4MEN1NPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | BACE1 1/4885PDE3B 970/4885PDE3A 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.